Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial
Publication
, Conference
Kalfa, TA; Telen, MJ; Saraf, SL; Brown, RC; Seu, KG; Larkin, SK; Soupene, E; Ribadeneira, MD; Schroeder, P; Wu, E; Kelly, P; Kuypers, FA
Published in: BRITISH JOURNAL OF HAEMATOLOGY
2022
Duke Scholars
Published In
BRITISH JOURNAL OF HAEMATOLOGY
EISSN
1365-2141
ISSN
0007-1048
Publication Date
2022
Volume
197
Start / End Page
12 / 13
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Kalfa, T. A., Telen, M. J., Saraf, S. L., Brown, R. C., Seu, K. G., Larkin, S. K., … Kuypers, F. A. (2022). Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial. In BRITISH JOURNAL OF HAEMATOLOGY (Vol. 197, pp. 12–13).
Kalfa, Theodosia A., Marilyn J. Telen, Santosh L. Saraf, R Clark Brown, Katie Giger Seu, Sandra K. Larkin, Eric Soupene, et al. “Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial.” In BRITISH JOURNAL OF HAEMATOLOGY, 197:12–13, 2022.
Kalfa TA, Telen MJ, Saraf SL, Brown RC, Seu KG, Larkin SK, et al. Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial. In: BRITISH JOURNAL OF HAEMATOLOGY. 2022. p. 12–3.
Kalfa, Theodosia A., et al. “Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial.” BRITISH JOURNAL OF HAEMATOLOGY, vol. 197, 2022, pp. 12–13.
Kalfa TA, Telen MJ, Saraf SL, Brown RC, Seu KG, Larkin SK, Soupene E, Ribadeneira MD, Schroeder P, Wu E, Kelly P, Kuypers FA. Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial. BRITISH JOURNAL OF HAEMATOLOGY. 2022. p. 12–13.
Published In
BRITISH JOURNAL OF HAEMATOLOGY
EISSN
1365-2141
ISSN
0007-1048
Publication Date
2022
Volume
197
Start / End Page
12 / 13
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology